LATAM Challenges and Recommendations
for PARPi Treatment in mCRPC: An expert overview

In Latin America, prostate cancer is the third most common cancer overall and the most frequent among men, with the highest mortality rate among all cancers. In 2020, there were approximately 214,000 new cases and 57,000 deaths from prostate cancer in the region. Patients with metastatic disease that is resistant to cure by castration (mCRPC) now have multiple therapeutic options, including poly-ADP ribose polymerase inhibitors (PARPis) (olaparib, talazoparib, rucaparib, and niraparib). These treatment advances present new challenges, such as developing monitoring protocols for early detection of disease progression and the transition from mCSPC to mCRPC.

To investigate this issue of timely access to PARPis in Latin America, the Americas Health Foundation conducted a virtual meeting with eight regional specialists (oncologists and pathologists) to develop a manuscript to assess the landscape of mCRPC diagnosis and treatment and provide recommendations to improve access to PARPis. The resulting manuscript, “LATAM Challenges and Recommendations for PARPi treatment in mCRPC: An expert overview,” is under review for publication.

Lead author: Rodolfo Borges dos Reis

Journal: JCO GO